AMARILLO, TX--(MARKET WIRE)--Jul 24, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTC BB:AMAR.OB - News) today announced that it has retained Commonwealth Associates to provide general financial consulting services and assist with capital formation to accelerate ABI’s ongoing Phase 2 clinical trials in oral warts in HIV+ patients and its Behcet’s Disease study.
